Outcome measures in acute gout: A systematic literature review

Journal of Rheumatology

Volumn 41, Issue 3, 2014, Pages 558-568

  Dalbeth, Nicola ^a   Zhong, Cathy S ^a   Grainger, Rebecca ^b   Khanna, Dinesh ^c   Khanna, Puja P ^c   Singh, Jasvinder A ^d   McQueen, Fiona M ^a   Taylor, William J ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Gout; Measurement; Outcome; Pain

Indexed keywords

ARTHROPATHY; DISEASE ASSOCIATION; GOUT; HUMAN; JOINT LIMITATION; JOINT SWELLING; JOINT TENDERNESS; LIKERT SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PAIN; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PATIENT GLOBAL ASSESSMENT OF RESPONSE TO TREATMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE;

GOUT; MEASUREMENT; OUTCOME; PAIN;

DISABILITY EVALUATION; GOUT; GOUT SUPPRESSANTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84895450372     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131244     Document Type: Review

References (61)

1. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41. (Pubitemid 43372104)
2. Dalbeth N, McQueen FM, Singh JA, MacDonald PA, Edwards NL, Schumacher HR Jr., et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol 2011;38:1458-61.
3. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, et al. Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009;36:2346-55.
4. Schumacher HR Jr., Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-5. (Pubitemid 41780667)
5. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
6. Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, et al. Outcome evaluations in gout. J Rheumatol 2007;34:1381-5. (Pubitemid 46898125)
7. Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 2011;38:1452-7.
8. Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR Jr., et al. Serum urate in chronic gout-will it be the first validated soluble biomarker in rheumatology? J Rheumatol 2011;38:1462-6.
9. Taylor WJ, Schumacher HR Jr., Baraf HS, Chapman P, Stamp L, Doherty M, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008;67:888-91. (Pubitemid 351829395)
10. Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, et al. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol 2011;38:1467-70.
11. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.
12. Khanna P, Singh MK, FitzGerald JD, Bae S, Prakash S, Kaldas M, et al. Pharmacological treatment of acute gout: a systematic review [abstract]. Arthritis Rheum 2011;63:S400.
13. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
14. Schlesinger N, Brown JP, Bardin T, Kiechle T, Shpilsky A, Alten R, et al. Comparison of pain intensity, incidence of new flares, safety and tolerability of canakinumab vs triamcinolone acetonide in gouty arthritis patients with cardiovascular diseases or with cardiovascular risk factors [abstract]. Arthritis Rheum; 2011;63:S401.
15. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301-4. (Pubitemid 18014682)
16. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1987;24:33-6. (Pubitemid 17087672)
17. Schumacher HR Jr., Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92. (Pubitemid 34666615)
18. Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011;13:R53.
19. Schumacher HR, Berger M, Li-Yu J, Perez-Ruiz F, Burgos Vargas RB, Li C. Efficacy and tolerability of celecoxib in the treatment of moderate to extreme pain associated with acute gouty arthritis: a randomized controlled trial [abstract]. Arthritis Rheum 2010;62 Suppl 10:S63.
20. Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606. (Pubitemid 38202232)
21. Marcolongo R, Lucchese M, Caruso I, Fumagalli M, Bruni G, Sacchetti G. Intravenous indoprofen for prompt relief of acute gout: a regimen-finding study. J Int Med Res 1980;8:326-32. (Pubitemid 10018729)
22. Barclay CA, Traballi CA. Evaluation of tenoxicam in rheumatology - clinical trial results in Argentina and Brazil. Eur J Rheumatol Inflamm 1987;9:26-50. (Pubitemid 18059062)
23. Tumrasvin T, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. J Med Assoc Thai 1985;68:111-6. (Pubitemid 15003099)
24. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
25. Lederman R. A double-blind comparison of Etodolac (Lodine®) and high doses of naproxen in the treatment of acute gout. Adv Ther 1990;7:344-54.
26. Rome K, Frecklington M, McNair P, Gow P, Dalbeth N. Foot pain, impairment, and disability in patients with acute gout flares: A prospective observational study. Arthritis Care Res 2012;64:384-8.
27. Schlesinger N, Norquist JM, Holmes R, Boice J, Watson DJ. Validation of a patient-reported assessment of pain in acute gouty arthritis [abstract]. Ann Rheum Dis 2007;66 Suppl II:234.
28. Chou CT, Kuo SC. The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol. Am J Chin Med 1995;23:261-71.
29. Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal clinically important Difference. J Rheumatol 2001;28:400-5.
30. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7. (Pubitemid 46601694)
31. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4. (Pubitemid 34118783)
32. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60. (Pubitemid 351736009)
33. Schlesinger N, Lin HY, Mysler EF, Puig J, De Meulemeester M, Balfour A, et al. Long-term safety and efficacy of canakinumab (ACZ885) in the prevention of flares in gouty arthritis patients [abstract]. Ann Rheum Dis 2011;70 Suppl 3:181.
34. Schlesinger N, Schumacher HR, Bardin T, Alten R, Bloch M, Brown JP, et al. Efficacy of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients: Results of the b-relieved ii study (response in acute flare and in prevention of episodes of re-flare in gout) [abstract]. Ann Rheum Dis 2010;69 Suppl 3:121.
35. So A, Alten R, Bardin T, Schumacher H, Bloch M, Rolfe A, et al. A controlled trial of canakinumab vs triamcinolone acetonide in acute gouty arthritis patients: results of the b-relieved study (response in acute flare and in prevention of episodes of re-flare in gout) [abstract]. Ann Rheum Dis 2011;70 Suppl 3:104.
36. Sunkureddi P, Bardin T, Alten R, Schlesinger N, Bloch M, Kiechle T, et al. Effect of IL-1 inhibition with canakinumab compared to triamcinolone acetonide on pain intensity and new flares in gouty arthritis patients with chronic kidney disease stage 2-5 [abstract]. Arthritis Rheum 2011;63:S398.
37. Bochev B, Toncheva A. Diclofenac Duo 0.075 for treatment of patients with coxarthrosis, gonarthrosis and gout. Ortopediya Travmatologiya 2003;39:65-70. (Pubitemid 37070976)
38. Shrestha M, Chiu MJ, Martin RL, Cush JJ, Wainscott MS. Treatment of acute gouty arthritis with intramuscular ketorolac tromethamine. Am J Emerg Med 1994;12:454-5. (Pubitemid 24215785)
39. Zou R, Zhang HX, Zhang TF. Comparative study on treatment of acute gouty arthritis by electroacupuncture with different frequency. Chin J Integr Med 2006;12:212-4. (Pubitemid 44534881)
40. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999;26:2285-6. (Pubitemid 29487039)
41. Cheng TT, Lai HM, Chiu CK, Chem YC. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399-406.
42. Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin 2007;23:1685-91. (Pubitemid 47122178)
43. Ruotsi A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scand J Rheumatol Suppl 1978:15-7. (Pubitemid 8387406)
44. Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg 3 times daily for the treatment of acute flares of gout. Rheumatology 2007;46:1126-32. (Pubitemid 47050616)
45. Terkeltaub R, Schumacher R, Curtis C, Patterson N, Evans R, Wang J, et al. Evaluation of rilonacept in patients with gouty arthritis experiencing an acute gout attack [abstract]. Arthritis Rheum 2010;62 Suppl 10:S64.
46. Ambanelli U, Bassi G, Bianchi V, Carcassi U, Caruso I, Colombo B, et al. Indoprofen in rheumatic patients with acute episodes: a multicentre trial. J Int Med Res 1982;10:399-407. (Pubitemid 13247444)
47. Caruso I, Fumagalli M, Marcolongo R, Sacchetti G. Indoprofen for acute gouty arthritis. Arthritis Rheum 1977;20:1438-9.
48. Mease PJ, Willkens RF. Treatment of acute gout with oxaprozin. Semin Arthritis Rheum 1986;15:86-9. (Pubitemid 16110280)
49. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6.
50. Douglas G, Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Ann Phys Med 1970;10:275-80.
51. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittelforschung 1983;33:641-3. (Pubitemid 13127047)
52. Katona G, Burgos-Vargas R. Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect. Drugs 1988;35 Suppl 1:72-80. (Pubitemid 18061951)
53. Shi XD, Li GC, Qian ZX, Jin ZQ, Song Y. Randomized and controlled clinical study of modified prescriptions of Simiao Pill in the treatment of acute gouty arthritis. Chin J Integr Med 2008;14:17-22. (Pubitemid 351488144)
54. Cobra CJ, Cobra JF, Cobra Neto C. Use of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflamm 1983;6:126-33. (Pubitemid 13117550)
55. Murphy JE. Piroxicam in the treatment of acute gout: a multicentre open study in general practice. J Int Med Res 1979;7:507-10. (Pubitemid 10165924)
56. Tausch G, Eberl R. Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflamm 1978;1:365-8. (Pubitemid 10180837)
57. Willkens RF, Case JB, Huix FJ. The treatment of acute gout with naproxen. J Clin Pharmacol 1975;15:363-6.
58. Lomen PL, Turner LF, Lamborn KR, Winblad MA, Sack RL, Brinn EL. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986;80:134-9. (Pubitemid 16044387)
59. Valdes EF. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987;9:133-6. (Pubitemid 18059081)
60. Fletcher MA, Wade AG. Clinical experience with isoxicam in patients with acute gout. Br J Clin Pract 1985;39:108-13. (Pubitemid 16143046)
61. Molina J. Fentiazac in acute gouty arthritis. Clin Ther 1985;7:327-33. (Pubitemid 15074501)